The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
Arkel Y, Paidas M, Ku D. The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagulation & Fibrinolysis 2002, 13: 199-205. PMID: 11943933, DOI: 10.1097/00001721-200204000-00005.Peer-Reviewed Original ResearchMeSH KeywordsActivated Protein C ResistanceAdolescentAdultAgedAged, 80 and overAntiphospholipid SyndromeAntithrombin IIIAntithrombin III DeficiencyAutoimmune DiseasesBiomarkersEnzyme-Linked Immunosorbent AssayFactor VFemaleFibrinFibrin Fibrinogen Degradation ProductsHumansHyperhomocysteinemiaMaleMiddle AgedPeptide FragmentsPeptide HydrolasesProtein C DeficiencyProtein S DeficiencyProthrombinRiskSolubilityThrombophiliaConceptsCoagulation activation markersActivation markersAssessment of hypercoagulabilityPercentage of patientsProthrombotic disordersVascular eventsConsecutive patientsThrombophilic abnormalitiesThrombotic riskPatientsSoluble fibrin polymersTPP levelsMean levelsMarkersAbnormalitiesFibrin polymersHypercoagulability